Trial · NCT01154140
Results by group270
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 270
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) Based on IRR | Crizotinib | 10.9 | 95% Confidence Interval 8.3 to 13.9 | months | |
| Progression-Free Survival (PFS) Based on IRR | Chemotherapy | 7.0 | 95% Confidence Interval 6.8 to 8.2 | months | |
| Overall Survival (OS) | Crizotinib | NA | 95% Confidence Interval 45.8 to NA | months | |
| Overall Survival (OS) | Chemotherapy | 47.5 | 95% Confidence Interval 32.2 to NA | months | |
| Overall Survival Probability at Month 12 and 18 | Crizotinib | Month 12 | 83.5 | 95% Confidence Interval 77.0 to 88.3 | percent probability |
| Overall Survival Probability at Month 12 and 18 | Chemotherapy | Month 12 | 78.4 | 95% Confidence Interval 71.3 to 83.9 | percent probability |
| Overall Survival Probability at Month 12 and 18 | Crizotinib | Month 18 | 71.5 | 95% Confidence Interval 64.0 to 77.7 | percent probability |
| Overall Survival Probability at Month 12 and 18 | Chemotherapy | Month 18 | 66.6 | 95% Confidence Interval 58.8 to 73.2 | percent probability |
| Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by IRR | Crizotinib | 74.4 | 95% Confidence Interval 67.2 to 80.8 | percentage of participants | |
| Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by IRR | Chemotherapy | 45.0 | 95% Confidence Interval 37.4 to 52.8 | percentage of participants | |
| Duration of Response (DR) Based on IRR | Crizotinib | 49.0 | 95% Confidence Interval 35.1 to 60.0 | weeks | |
| Duration of Response (DR) Based on IRR | Chemotherapy | 22.9 | 95% Confidence Interval 18.0 to 25.1 | weeks | |
| Time to Tumor Response (TTR) Based on IRR | Crizotinib | 6.1 | Full Range 2.7 to 41.4 | weeks | |
| Time to Tumor Response (TTR) Based on IRR | Chemotherapy | 12.1 | Full Range 5.1 to 36.7 | weeks | |
| Percentage of Participants With Disease Control at Week 12 Based on IRR | Crizotinib | 78.5 | 95% Confidence Interval 71.6 to 84.4 | percentage of participants | |
| Percentage of Participants With Disease Control at Week 12 Based on IRR | Chemotherapy | 68.4 | 95% Confidence Interval 60.9 to 75.3 | percentage of participants | |
| Time to Progression (TTP) Based on IRR | Crizotinib | 13.6 | 95% Confidence Interval 8.5 to 15.0 | months | |
| Time to Progression (TTP) Based on IRR | Chemotherapy | 7.0 | 95% Confidence Interval 6.8 to 8.3 | months | |
| Time to Intracranial Progression (IC-TTP) Based on IRR | Crizotinib | NA | 95% Confidence Interval NA to NA | months | |
| Time to Intracranial Progression (IC-TTP) Based on IRR | Chemotherapy | 17.8 | 95% Confidence Interval 13.9 to NA | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01154140/results